HQL
abrdn Life Sciences Investors
NYSE · Financial Services · Asset Management · US
$19.41
−0.82%Forward multiples
Based on analyst estimates
- P/E forward
- —
- P/E 2026E
- —
- P/E 2027E
- —
- P/E 2028E
- —
- P/S forward
- —
Trailing multiples
Trailing twelve months
- P/E TTM
- 6.56x
- PEG TTM
- —
- Price / book
- 1.00x
- Price / sales
- 6.49x
- Price / cash flow
- -241.53x
Enterprise value
- Enterprise value
- $559.6M
- EV / sales
- 6.48x
- EV / EBITDA
- 6.54x
- EV / EBIT
- 6.54x
- Market cap
- $560.4M
Trailing, forward and enterprise-value multiples for the requested listing · Data as of Mar 1, 2026